BridgeBio Pharma (BBIO) Cash & Equivalents (2018 - 2026)
BridgeBio Pharma (BBIO) posted Cash & Equivalents of $879.9 million for Q1 2026, up 54.33% sequentially from $570.1 million in Q4 2025, and up 62.76% YoY from $540.6 million in Q1 2025.
BridgeBio Pharma (BBIO) Cash & Equivalents (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Cash & Equivalents for 9 years, with the latest figure at $879.9 million in Q1 2026.
- Quarterly Cash & Equivalents rose 62.76% year-over-year to $879.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $879.9 million (up 62.76% YoY) and the FY2025 annual result came in at $570.1 million, up 58.46% from the prior year.
- Cash & Equivalents improved to $879.9 million in Q1 2026 per BBIO's latest filing, from $570.1 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $879.9 million in Q1 2026 and troughed at $266.3 million in Q3 2024.
- A 5-year average of $460.3 million and a median of $408.0 million in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 167.95% in 2022, then plunged 47.28% in 2024.
- Over 5 years, Cash & Equivalents stood at $376.7 million in 2022, then fell by 0.2% to $375.9 million in 2023, then declined by 4.3% to $359.8 million in 2024, then soared by 58.46% to $570.1 million in 2025, then soared by 54.33% to $879.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $879.9 million, $570.1 million, and $283.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | 677.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 677.91 Mn |
| Mar 31, 2026 | 879.89 Mn |
| Dec 31, 2025 | 570.12 Mn |
| Sep 30, 2025 | 283.34 Mn |
| Jun 30, 2025 | 748.95 Mn |
| Mar 31, 2025 | 540.60 Mn |
| Dec 31, 2024 | 359.78 Mn |
| Sep 30, 2024 | 266.32 Mn |
| Jun 30, 2024 | 407.96 Mn |
| Mar 31, 2024 | 475.22 Mn |
| Dec 31, 2023 | 375.94 Mn |
| Sep 30, 2023 | 505.21 Mn |
| Jun 30, 2023 | 302.44 Mn |
| Mar 31, 2023 | 407.37 Mn |
| Dec 31, 2022 | 376.69 Mn |
| Sep 30, 2022 | 483.24 Mn |
| Jun 30, 2022 | 470.10 Mn |
| Mar 31, 2022 | 371.55 Mn |
| Dec 31, 2021 | 393.77 Mn |
| Sep 30, 2021 | 180.35 Mn |